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AbsTrACT
Objective recently, tumours with microsatellite 
instability (Msi)/defective Dna mismatch repair (dMMr) 
have gained considerable interest due to the success 
of immunotherapy in this molecular setting. here, we 
aim to clarify clinical- pathological and/or molecular 
features of this tumour subgroup through a systematic 
review coupled with a comparative analysis with existing 
databases, also providing indications for a correct 
approach to the clinical identification of Msi/dMMr 
pancreatic ductal adenocarcinoma (PDac).
Design PubMed, scOPUs and embase were searched 
for studies reporting data on Msi/dMMr in PDac up to 
30 november 2019. histological and molecular data of 
Msi/dMMr PDac were compared with non- Msi/dMMr 
PDac and with PDac reference cohorts (including 
seer database and The cancer genome atlas research 
network - Tcga project).
results Overall, 34 studies with 8323 patients with 
PDac were included in the systematic review. Msi/
dMMr demonstrated a very low prevalence in PDac 
(around 1%–2%). compared with conventional PDac, 
Msi/dMMr PDac resulted strongly associated with 
medullary and mucinous/colloid histology (p<0.01) and 
with a KRAS/TP53 wild- type molecular background 
(p<0.01), with more common JAK genes mutations. Data 
on survival are still unclear.
Conclusion PDac showing typical medullary 
or mucinous/colloid histology should be routinely 
examined for Msi/dMMr status using specific tests 
(immunohistochemistry, followed by Msi- Pcr in cases 
with doubtful results). next- generation sequencing 
(ngs) should be adopted either where there is limited 
tissue or as part of ngs tumour profiling in the context 
of precision oncology, acknowledging that conventional 
histology of PDac may rarely harbour Msi/dMMr.
InTrODuCTIOn
Pancreatic cancer is a highly malignant disease that 
is projected to become the second most common 
cause of cancer- related death worldwide in the next 
decade.1 Pancreatic ductal adenocarcinoma (PDAC) 
is the most common type of pancreatic malignancy, 
responsible for >95% of deaths from pancre-
atic cancer.1 A large proportion (>75%–80%) of 
patients with PDAC present with locally advanced 
or metastatic disease, at time of diagnosis, there-
fore a surgical resection with curative intent is not 
possible. Even with radical resection and adjuvant 
chemotherapy, 5- year survival remains very poor 
significance of this study
What is already known on this subject?
 ► Microsatellite instability (MSI) has recently 
gained considerable interest due to the success 
of immunotherapy in this molecular setting.
 ► MSI in pancreatic ductal adenocarcinoma 
(PDAC) is a molecular alteration with variable 
reported frequency.
 ► Tumours with MSI have perhaps a better 
prognosis and usually show a good response to 
immunotherapy.
What are the new findings?
 ► MSI in PDAC is very rare (around 1%–2% of 
cases).
 ► MSI PDAC are strongly associated with 
medullary and mucinous/colloid histology and 
are usually KRAS- TP53 wild type.
 ► JAK and KMT2 genes mutations are more 
common in this tumour type.
 ► Data on survival of MSI PDAC are still unclear.
How might it impact on clinical practice in the 
foreseeable future?
 ► The results of the present study show that MSI 
should be determined as part of a first- line 
routine analysis (immunohistochemistry; MSI- 
PCR in case of doubtful results; next- generation 
sequencing (NGS) in case of limited tissue) in 
PDAC with typical histology.
 ► In the context of precision oncology, for 
conventional PDAC, MSI should be assessed 
using NGS for analysing all potential 
therapeutic targets.
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(about 20%).1 To improve survival of patients with PDAC, new 
therapeutic strategies are urgently needed. One of the main 
focuses of current research in this field aims at identifying new 
molecular targets and subgroups of PDAC that may benefit from 
personalised treatment, opening new landscapes for the so- called 
‘precision oncology’.2
In this context, tumours with microsatellite instability (MSI)/
defective DNA mismatch repair (dMMR) represent a molecular 
subgroup of malignancies with novel therapeutic opportunities 
given the significant results of immunotherapy recently reported 
in this setting.3 4 The mismatch repair system is a mechanism 
that recognises and repairs the erroneous insertion, deletion and 
misincorporation of bases that can arise during DNA replication 
and recombination and in some conditions of DNA damage.3 4 
Alterations affecting such a mechanism are defined as dMMR. 
Microsatellites are short and very repetitive sequences of 1–6 
DNA base pairs that are found throughout the genome. Due to 
the repetitive nature, their alteration is typically present in cases 
of dMMR and is defined as MSI.3 4 Tumours with MSI/dMMR 
usually accumulate thousands of mutations and are characterised 
by a hypermutated genome. Interestingly, this condition can be 
tested using immunohistochemistry (IHC) and molecular tests, 
including classic (PCR)- based microsatellite testing and novel 
next- generation sequencing (NGS) approaches.4
MSI/dMMR occurs in a respectable proportion of colorectal 
cancers (about 15%), is associated with distinct biological 
behaviour and differential response to different therapies, and 
thus routine screening is advocated in guidelines.4 For PDAC, 
however, its frequency varies largely among different studies 
and a complete definition of MSI/dMMR PDACs is still lacking. 
Therefore, with this systematic review, coupled with a compara-
tive analysis with existing databases, we aim at clarifying the true 
frequency of MSI/dMMR in PDAC, also highlighting the specific 
histological, immunohistochemical and molecular features of 
this tumour subtype.
MATerIAls AnD MeTHODs
This systematic review adhered to the Meta- analyses Of Obser-
vational Studies in Epidemiology (MOOSE) guidelines and 
Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA) statement,5 6 following a predetermined 
protocol.
Inclusion and exclusion criteria
Studies were eligible if they met the following criteria: (1) orig-
inal and complete study on human pancreatic cancer; (2) clear 
description of the method(s) used for testing MSI/dMMR; (3) 
clear report of the total number of cases of pancreatic cancer and 
the number of cases of MSI/dMMR pancreatic cancer; (4) publi-
cation in a peer- review journal in English language. Exclusion 
criteria were: (1) cancers from organs other than pancreas; (2) 
no invasive cancer (eg, intraductal papillary mucinous neoplasm 
(IPMN)), (3) no data regarding MSI/dMMR analysis; (4) case 
reports, abstracts and in vitro or animal studies.
Data sources and literature search strategy
Two investigators (CL, AS) independently searched PubMed, 
SCOPUS and Embase up to 30 November 2019. The search 
terms used in PubMed included combinations of the following 
keywords: (‘MSI’ OR ‘microsatellite’ OR ‘dMMR’ OR 
‘mismatch’) AND (‘pancreatic’ OR ‘pancreas’). A similar search 
was carried out in SCOPUS and Embase. We also considered 
the reference lists of all included articles and of previous related 
reviews.
study selection
Following the searches as outlined above, after removal of dupli-
cates, two independent reviewers (CL, AS) screened titles and 
abstracts of all potentially eligible articles. The two authors 
applied the eligibility criteria, reviewed the full texts and a final 
list of selected articles was reached through consensus with a 
third author (RTL). In case of doubled cohort, we selected the 
larger cohort and the most recent paper.
Data extraction, synthesis and statistical analysis
Two authors were involved in data extraction in a standardised 
Microsoft Excel database. Specifically, one author (CL) extracted 
data from the included articles and a second independent author 
(AS) validated the data. For each article, information about 
authors, year of publication, country of origin of the analysed 
cohort, number of patients, number of MSI/dMMR tumours, 
histological and molecular data on MSI/dMMR tumours, 
methods for MSI/dMMR testing, presence of Lynch syndrome 
and survival outcomes was extracted. Finally, all extracted data 
were reported and summarised in table 1, and then analysed, 
interpreted and discussed by all authors. To assess for differences 
in histological features between PDAC in unselected patients 
versus those with dMMR/MSI, a Fisher’s exact test was used to 
compare our results with a large published cohort, specifically 
reporting the histological subtypes of patients with familial and 
sporadic pancreatic cancers.7 This method has also been recently 
used by Hruban et al to compare the histology of an orig-
inal cohort of ATM- mutated PDAC with that of conventional 
PDAC.8 To further corroborate our results, a comparison was 
also carried out considering patients from the SEER database 
as another validation cohort.9 In order to assess for differences 
in additional molecular features between PDAC in unselected 
patients versus those with dMMR/MSI, a Fisher’s exact test 
was used to compare our results with data published by The 
Cancer Genome Atlas Research Network (TCGA), which we 
used as a reference cohort.10 Furthermore, availing the manu-
scripts selected for this systematic review to assess differences 
in terms of survival, a meta- analysis comparing the prognostic 
outcomes of MSI/dMMR PDAC versus non- MSI/dMMR PDAC 
was performed using the programmes ‘Comprehensive Meta- 
Analysis’ and ‘RevMan 5’ (http://www. meta- analysis. com, last 
access 9 March 2020). Lastly, in order to define the presence of 
any potentially specific driver gene in MSI/dMMR PDAC, we 
analysed the existing literature on genetic drivers in MSI/dMMR 
tumours and reviewed, using linear comparisons, all available 
sequencing data from our systematic review.
resulTs
Among 1712 potential eligible studies, 54 full- text articles were 
retrieved. Of them, 34 studies were eligible for this systematic 
review (table 1).11–44 As reported in table 1, the 34 eligible studies 
included a total of 8323 patients. Of these, the total number of 
reported MSI/dMMR PDACs was 218, which corresponds to 
2.61% of all patients with PDAC. This percentage represents 
a slight overestimation of the real prevalence of MSI/dMMR 
PDAC, since some studies are focused on PDAC subtypes appar-
ently enriched by this molecular alteration. After removing those 
studies, the real prevalence of MSI/dMMR tumours was 2.53%. 
Regarding the methodology to assess MSI/dMMR in PDAC, 
23 studies used PCR, whereas 13 used IHC and 8 NGS (some 
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studies used more than one method for MSI/dMMR assessment; 
table 1). However, the methods applied in different studies 
greatly varied, even in the case of the same category of analysis. 
In fact, 14 different PCRs were described, with only 6 studies 
(26% of all PCR- based studies) using the standardised NCI/MSI 
PCR markers.4 A similar situation was observed for IHC, with 
four different types of analyses and only seven studies (53.8%) 
using the standardised antibodies.
Considering the prevalence of MSI/dMMR alterations based 
on the methods used for its determination, prevalence was lower 
in studies that used NGS (68/6030, 1.1%) alone or in combina-
tion compared with studies using PCR and/or IHC (150/2293, 
6.5%), reaching a statistically significant value (Fisher’s exact 
test; p<0.01).
The first aspect to be analysed considering histopathological 
data is the pancreatic site in which MSI/dMMR tumours arise. 
Based on reported data of tumour location in the pancreas, the 
vast majority of MSI/dMMR PDACs (78%) have been described 
in the pancreatic head. The prevalence of tumour location in 
MSI/dMMR tumours was not statistically significantly different 
from the reference cohort of familial and sporadic PDACs nor 
from SEER database. Next, regarding the histology of MSI/
dMMR tumours, conventional PDAC represented the 67.9% 
of the whole cohort of this systematic review, whereas 18.9% 
were medullary PDAC, 11.3% were mucinous/colloid PDAC and 
1.9 were of the signet ring variant. The prevalence of medullary 
and mucinous/colloid variant of PDAC was higher than observed 
in patients with familial and sporadic PDAC in the reference 
cohorts of Singhi et al7 and in the SEER database (p<0.01),9 
indicating that these subtypes arise more typically in the MSI/
dMMR molecular background.
Some studies also reported molecular data in addition to MSI/
dMMR status. The vast majority of this subgroup of PDAC were 
wild type for KRAS (22/33, 66.6%) and TP53 (14/21, 66.6%): 
these values were statistically significantly different from the 
usual molecular profile of PDAC, as resulted from a comparison 
with data from TCGA cohort (p<0.01). Regarding the studies 
that also assessed tumour mutational burden (TMB),36 40 44 
85.7% of MSI/dMMR PDAC also showed high TMB. Singhi 
et al also reported results from NGS of a large PDAC cohort 
(3594 cases): interestingly, one case among the three detected 
MSI/dMMR PDACs harboured the druggable FGFR2- POC1B 
fusion.44
Regarding the presence of any potential specific driver genes 
in MSI/dMMR PDAC, we found a bi- univocal correspondence 
regarding genes belonging to the JAK/STAT pathway and 
those of KMT2 family. Indeed, these have been described as 
frequently mutated in MSI/dMMR cancers of different extra- 
pancreatic sites45 46; the review of all molecular data of MSI/
dMMR PDAC showed the involvement of the JAK/STAT 
pathway also in MSI/dMMR PDAC, given that the paper by 
Wartenberg et al,39 reported a higher mutation rate of JAK3 
specifically in this genetic subgroup (3/5 MSI/dMMR cases vs 
4/105 microsatellite- stable PDAC, p<0.01, Fisher’s exact test; 
all these cases were KRAS mutated), and in the paper by Singhi 
et al, two of the three reported MSI/dMMR PDAC harboured a 
JAK1 mutation (2/3 MSI/dMMR PDAC vs 0/608 microsatellite- 
stable PDAC with actionable targets, p<0.01, Fisher’s exact 
test).44 Furthermore, we found that alterations affecting the 
KMT2 family were involved as well, since 3/3 MSI/dMMR 
cases described by Singhi et al harboured KMT2 mutations 
(two cases with KMT2D and one case KMT2C mutation; 3/3 
KMT2 mutated MSI/dMMR PDAC vs 32/608 KMT2 mutated 
microsatellite- stable PDAC with actionable targets, p<0.01, 
Fisher’s exact test; the MSI/dMMR and KMT2 mutated cases 
were KRAS wild type).
Regarding the association of MSI/dMMR pancreatic cancers 
with Lynch syndrome, a total of 27 cases were reported in the 
background of this genetic condition. Integrating histological 
data when available (18 cases) from the original papers, 9/18 
(50%) had conventional histology, whereas 4/18 (22.2%) were 
medullary and 5/18 (27.7%) were mucinous/colloid. Comparing 
this prevalence with that of all the non- hereditary MSI/dMMR 
PDACs, there were no statistically significant differences between 
the two cohorts.
The final important aspect to analyse is regarding the survival 
of patients with MSI/dMMR PDAC. We performed a meta- 
analysis for calculating the relative risks for overall survival (OS), 
disease- specific survival (DSS) and also for ‘all- types’ of survival 
(ATS, putting together OS and disease- free survival), to find 
any potential association between MSI/dMMR and prognosis in 
PDAC. No data for calculating the HRs were present. The results 
on risk ratios showed that there is not a significant impact on the 
survival for MSI/dMMR in PDAC (OS: p=0.36; DSS: p=0.50; 
ATS: p=0.16 ; online supplementary figures 1–3). At the same 
time, it is also of importance to highlight the high heterogeneity 
of the results (I2=86%, 88% and 63% for OS, DSS and ATS, 
respectively) and that there are too few data (only five manu-
scripts) to draw any definitive conclusion.
DIsCussIOn
With this systematic review- based study, we have definitively 
clarified that MSI/dMMR in PDAC: i) has a very low preva-
lence (1%–2%); ii) is strongly associated with medullary and 
mucinous/colloid histology; iii) is associated with a KRAS/TP53 
wild- type molecular background, and more common JAK (JAK1 
and JAK3) and KMT2 (KMT2C and KMT2D) genes mutations 
and iv) does not show a clear survival benefit, as for example in 
colorectal cancer.
Regarding the prevalence of MSI/dMMR in PDAC, it is around 
2.5% considering all published data, but this value goes down 
significantly to 1.1% when considering only studies that use more 
recently developed, standardised and validated NGS techniques. 
Thus, the percentage of 2.5% appears as an overestimation of 
the real MSI/dMMR prevalence in PDAC. This may be due, at 
least in part, to the different and not validated methods used in 
the past for MSI/dMMR assessment. Indeed, 15 different PCR 
tests and 4 different IHC panels have been used considering all 
the studies selected for this systematic review. However, only six 
studies based on IHC/PCR used the suggested and standardised 
IHC antibodies and/or NCI/MSI PCR markers.9 47 48 It is also 
important to acknowledge that the NCI guidelines regarding 
MSI testing were first published in 1998,47 thus papers published 
up to this time could not have adopted an NCI panel. The most 
important MSI marker in the initial NCI guidelines was BAT26, 
which is a highly sensitive and specific marker of MSI. Some 
early manuscripts reported high levels of MSI- likely but these 
were potentially due to inappropriate microsatellite markers. 
Contrary to this situation, all studies based on NGS appeared 
more reliable: they used NGS coupled with validation tools, 
analysed larger cohorts and gave more homogeneous results, 
with a range of MSI/dMMR prevalence from 0% to 1.6% (mean 
value of 1.1%). Based on these considerations, the real preva-
lence of MSI/dMMR in PDAC could be reasonably considered 
to be around 1%–2%, or even less (<1%). Furthermore, along 
these lines, it is evident that the use of reliable and standardised 
procedures is mandatory.
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Figure 1 A classical example of a MSI/dMMR medullary 
pancreatic ductal adenocarcinoma. The medullary variant is a typical 
histological aspect associated with MSI/dMMR in pancreatic ductal 
adenocarcinoma. At the immunohistochemical level, the loss of 
expression of one heterodimer of the mismatch repair proteins (MSH2 
with MSH6, MLH1 with PMS2) is a reliable surrogate of MSI. In this 
representative case, there is the loss of the expression of MSH2- MSH6 
proteins. (A) Medullary histology: this pattern is characterised by a 
syncytial growth with marked lymphocytes infiltration (H&E staining, 
original magnification: 4×). (B) Immunohistochemical analysis for MSH2 
shows the loss of the protein in tumour cells. The positive cells inside 
the tumour area are lymphocytes, endothelial and stromal cells (original 
magnification: 10×). (C, D) Immunohistochemical analysis for MLH1 (C) 
and PMS2 (D) shows positive staining also in tumour cells (expression 
of the protein; original magnification: 20×). (E) Immunohistochemical 
analysis for MSH6 shows the loss of expression of the protein in 
tumour cells. The positive cells inside the tumour area are lymphocytes, 
endothelial and stromal cells (original magnification: 10×). dMMR, 
defective mismatch repair; MSI, microsatellite instability.
Figure 2 A classical example of a MSI/dMMR mucinous/colloid 
pancreatic ductal adenocarcinoma. The mucinous/collolid variant is a 
typical histological aspect associated with MSI/dMMR in pancreatic 
ductal adenocarcinoma. At the immunohistochemical level, the loss 
of the expression of one heterodimer of the mismatch repair proteins 
(MSH2 with MSH6, MLH1 with PMS2) is a reliable surrogate of MSI. In 
this representative case, there is the loss of expression of MLH1- PMS2 
proteins. (A) Mucinous/colloid histology: this pattern is characterised 
by large mucin pools with floating tumour cells/clusters (H&E staining, 
original magnification: 10×). (B) Immunohistochemical analysis for 
MLH1 shows the loss of the protein in tumour cells. The positive cells in 
the periphery are lymphocytes, endothelial and stromal cells (original 
magnification: 20×). (C, D) Immunohistochemical analysis for MSH2 (C) 
and MSH6 (D) shows positive staining also in tumour cells (expression 
of the protein; original magnification: 20×). (E) Immunohistochemical 
analysis for PMS2 shows the loss of expression of the protein in tumour 
cells. The positive cells in the periphery are lymphocytes, endothelial and 
stromal cells (original magnification: 20×). dMMR, defective mismatch 
repair; MSI, microsatellite instability.
An important point concerns tumour site within the pancreas. 
There were no statistically significant differences between 
conventional PDAC and MSI/dMMR PDAC, with pancreatic 
head confirmed as the elective location also for this PDAC 
subgroup. However, this tumour location may also be responsible 
for the overestimation of the true prevalence of MSI/dMMR in 
PDAC. Indeed, large ampullary/periampullary- duodenal cancers 
with pancreatic infiltration may be misdiagnosed as PDAC (in 
these cases it could be very difficult to establish the real site of 
origin) and MSI/dMMR is a molecular alteration more typical of 
neoplasms with intestinal differentiation.9 49
Regarding the histology of MSI/dMMR PDAC, medullary 
and mucinous/colloid variants of PDAC resulted significantly 
more common in this PDAC subgroup (two representative cases, 
including the immunohistochemical pattern, are illustrated in 
figures 1 and 2). However, these histological subtypes are not 
always associated with MSI/dMMR. Indeed, medullary histology 
can be found in microsatellite stable PDAC, for example, in 
association with Epstein- Barr virus (EBV) infection.20 Similarly, 
mucinous/colloid features can be found in microsatellite stable 
PDAC, for example, in association with GNAS (also in associa-
tion with pre- existing IPMN) or germline- ATM mutations.8 38 50 
It should be reiterated here that medullary and colloid carci-
noma are significantly more common in the ampulla than in 
the pancreas, and considering the well- known proneness of 
ampullary cancers to be mistaken as pancreatic origin,51 in a case 
with this diagnosis, the possibility of a secondary invasion from 
the ampulla, or even a metastasis from the colon ought to be 
carefully excluded.52 However, due to the strong association of 
these two PDAC variants with MSI/dMMR, for cases of medul-
lary and mucinous/colloid histology, the final pathology report 
should be integrated with the assessment of MSI/dMMR status. 
This should be performed using IHC as first- line analysis, also 
following existing guidelines,4 and, only in the case of doubtful 
or not reliable IHC results, MSI- based PCR should be executed. 
Considering the different advantages and limitations of the 
methods of MSI testing in PDAC (which have been summarised 
in table 2), NGS is recommended as first- line analysis in the case 
of limited tissue, and in the context of precision oncology.
Taking into account the genetic profile of MSI/dMMR PDAC, 
this systematic review highlighted that the vast majority of this 
molecular subgroup is KRAS and TP53 wild type. This is a very 
unusual profile for PDAC, which calls for further genetic anal-
ysis for the selection of therapeutic strategies. Indeed, KRAS 
wild- type PDAC, although unusual, include a heterogeneous 
group of neoplasms that may have potential targets for precision 
medicine. These comprise MSI/dMMR, and other important 
genetic alterations, such as those involving BRAF gene, and 
kinase fusion genes (eg, FGFR2 and NTRK fusions).44 53 Notably, 
one case with FGFR2 fusion has been described in the context of 
MSI/dMMR.44 Moreover, TMB resulted high in the majority of 
MSI/dMMR PDAC, and this represents another variable strictly 
associated with benefits from immunotherapy. Further studies 
in PDAC should also address whether better response to immu-
notherapy could be reached where there is co- existence of MSI/
dMMR and high TMB, such as in colorectal cancer.54 We also 
found additional potential driver genes typically involved in MSI/
dMMR PDAC: JAK (JAK1 and JAK3) and KMT2 (KMT2C and 
KMT2D). JAK genes code for a homonymous family of kinases, 
which are required for the signalling of a host of immune modu-
lators in tumour, stromal and immune cells; alterations in this 
family have been associated with an immune evasion by tumour 
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Table 2 Advantages and limitations of the different methods for assessing MSI/dMMR status in pancreatic ductal adenocarcinoma
Advantages limitations
Immunohistochemistry
  Widely available and reliable in PDAC using the staining for the four classical 
MMR proteins MLH1, PMS2, MSH2, MSH6 (above all for surgical specimens—
‘large’ amount of tissue)
Suboptimal tissue fixation may impact its reliability.
  Economical Limited by antibodies available.
  Reproducible Limited by the amount of tissue. Limited/inadequate tissue can lead to false loss of MMR 
proteins in PDAC.
  Rapid turn- around time Can give false results (eg, loss of expression of one MMR protein) in case of the presence of 
a different partner of MMR proteins in the usual MLH1- PMS2 and MSH2- MSH6 heterodimers 
(eg, MLH1- PMS1, MSH2- MSH3).
  More sensitive than MSI- PCR testing in detecting absence of MSH6   
MSI- PCR
  Reproducible Not able to detect the specific mutated gene.
  Can detect MSI/dMMR tumours that have intact
  MMR protein staining on IHC
Less sensitive than MSI- PCR testing in detecting absence of MSH6.
  Rapid turnaround time   
NGS
  Reliable also in case of limited tissue/biopsy (also for EUS- FNB) Expensive.
  Can detect simultaneously specific somatic and germline mutations of different 
genes
Still not widely available.
  Can also be used to assess MSI and TMB Longer turnaround time.
  Can identify targetable mutations   
dMMR, defective mismatch repair; EUS- FNB, endoscopic ultrasound- guided fine- needle biopsy; IHC, immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability; 
NGS, next- generation sequencing; PDAC, pancreatic ductal adenocarcinoma; TMB, tumour mutational burden.
cells.45 KMT2 genes code for a homonymous family of methyl- 
transferases, which are the effectors of histone H3 methylation, 
one of the epigenetic mechanisms regulating gene transcrip-
tion.46 In case of mutations, both JAK and KMT2 genes have been 
already described as potential drivers in MSI/dMMR tumours of 
other sites,45 46 and we highlighted their potential involvement 
also in MSI/dMMR PDAC, further refining the knowledge on 
the genetic landscape of this tumour entity.
Regarding survival of MSI/dMMR patients with PDAC, this 
systematic review revealed that there are no significant improve-
ments in survival outcomes for this subgroup of patients. 
However, regarding this point, the results of our meta- analysis 
cannot be considered definitive, because available data on this 
aspect are still limited and also because of their high heteroge-
neity; further studies are needed to address this important point. 
Indeed, although MSI/dMMR is a well- recognised prognostic 
moderator of some cancers, with a strong association to better 
prognosis such as in colorectal, gastric, duodenal and ampullary 
cancers,4 in PDAC such survival improvement is not so clear. 
The morphological and genetic complexity of this tumour type 
and its high aggressiveness may explain only in part these find-
ings, indicating the probable presence of other still unknown but 
important factors along this line. However, the new opportuni-
ties of immunotherapy against MSI/dMMR tumours may open 
new important horizons for the prognosis also of patients with 
PDAC with this molecular alteration.
Regarding the clinical/therapeutic aspects related to MSI/
dMMR PDAC, it is important to note that the US Food and Drug 
Administration (FDA) has recently approved the PD-1 immune 
checkpoint inhibitor pembrolizumab for the ‘site- agnostic’ treat-
ment of MSI/dMMR tumours.55 This decision was no doubt 
based on scientific evidence from the initial observations in a 
cohort mostly including colorectal cancers,3 after further confir-
mation in the findings of KEYNOTE-158, a phase II basket trial 
on non- intestinal MSI tumours.56 Initially, among eight patients 
with MSI/dMMR PDAC, five of them showed objective responses 
(two complete and three partial). However, an update of the trial 
including a total of 22 MSI/dMMR patients with PDAC, showed 
only 4 out of 22 patients with objective responses (1 complete 
and 3 partial), which represented the lowest objective response 
among the different investigated cancers.57 These findings 
pointed out the potential differences, based on cancer site, of the 
response rate to immunotherapy of MSI/dMMR tumours and 
confirmed the complex biological and clinical nature of PDAC.
In conclusion, with this systematic review coupled with a 
comparative analysis with existing databases, we have definitively 
clarified the very low prevalence of MSI/dMMR in PDAC; this 
type of molecular alteration is strongly associated with medullary 
and mucinous/colloid histology, arises in a KRAS/TP53- wild type 
molecular background, with more common JAK and KMT2 genes 
mutations, and its association with a longer survival is controver-
sial. Due to its very low prevalence and also on the basis of this 
systematic review, MSI/dMMR should be determined as first- 
line analysis and with specific tests (IHC, then MSI- based PCR 
only in case of doubtful results; NGS in case of limited tissue) 
during PDAC routine diagnostic activity only in case of typical 
histology (medullary or mucinous/colloid). Conversely, to search 
for new potential targets for precision oncology (eg, the FGFR- 
POC1B fusion described in a MSI/dMMR PDAC or other targets 
in non- MSI/dMMR PDAC), MSI should be assessed as second- 
line action ideally using NGS, to permit additional simultaneous 
analysis and potentially provide more options for treatment.
Author affiliations
1Diagnostics and Public health, section of Pathology, University and hospital Trust of 
Verona, Verona, italy
2Pathology, University Medical center, Utrecht, The netherlands
3Pathology, radboud University Medical center, nijmegen, The netherlands
4sol goldman Pancreatic cancer research center, Department of Pathology, Johns 
hopkins University, Baltimore, Maryland, Usa
8 luchini c, et al. Gut 2020;0:1–9. doi:10.1136/gutjnl-2020-320726
Pancreas
5Pathology and immunology, Washington University in saint louis school of 
Medicine, saint louis, Missouri, Usa
6Pediatrics, Yonsei University college of Medicine, seoul, The republic of Korea
7general and Pancreatic surgery, University and hospital Trust of Verona, Verona, 
italy
8Pathology and laboratory Medicine, indiana University school of Medicine, 
indianapolis, indiana, Usa
9arc- net research center, University and hospital Trust of Verona, Verona, italy
10Pathology, Koç University hospital, istanbul, Turkey
11arc- net research center and Department of Diagnostics and Public health, 
section of Pathology, University and hospital Trust of Verona, Verona, italy
Acknowledgements This paper is dedicated to all the healthcare staff worldwide 
who are facing cancer and also the emergency of coronavirus and to all victims.
Contributors cl and as conceived the study. cl, laaB, rTl, Va and as: study 
design. cl, as and rTl: data extraction and elaboration. cl: statistical analysis. 
all authors: data interpretation and discussion. cl and as: manuscript writing. all 
authors: manuscript editing and final approval.
Funding This study is supported by associazione italiana ricerca sul cancro (airc 
5x1000 n. 12182) and Fondazione cariverona: Oncology Biobank Project ’antonio 
schiavi’ (prot. 203885/2017). VK is supported by the Dutch cancer society (KWF 
grant 2016, 10289).
Competing interests lDW has been a paid consultant for PgDx (Personal 
genome Diagnostics, Baltimore, MD, Usa). cl has been a paid expert- consultant on 
microsatellite instability for Bioscience communications (new York, new York, Usa).
Patient and public involvement Patients and/or the public were not involved in 
the design, conduct, reporting or dissemination plans of this research.
Patient consent for publication not required.
Provenance and peer review not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request. Data are 
available in a public, open access repository.
Open access This is an open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY- nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. see: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCID iDs
claudio luchini http:// orcid. org/ 0000- 0003- 4901- 4908
Valentyna Kryklyva http:// orcid. org/ 0000- 0002- 1020- 6606
aldo scarpa http:// orcid. org/ 0000- 0003- 1678- 739X
RefeRences
 1 Kamisawa T, Wood lD, itoi T, et al. Pancreatic cancer. The Lancet 2016;388:73–85.
 2 herbst B, Zheng l. Precision medicine in pancreatic cancer: treating every patient as 
an exception. Lancet Gastroenterol Hepatol 2019;4:805–10.
 3 le DT, Uram Jn, Wang h, et al. Pd-1 blockade in tumors with mismatch- repair 
deficiency. N Engl J Med 2015;372:2509–20.
 4 luchini c, Bibeau F, ligtenberg MJl, et al. esMO recommendations on microsatellite 
instability testing for immunotherapy in cancer, and its relationship with PD-1/PD- l1 
expression and tumour mutational burden: a systematic review- based approach. Ann 
Oncol 2019;30:1232–43.
 5 stroup DF, Berlin Ja, Morton sc, et al. Meta- analysis of observational studies in 
epidemiology: a proposal for reporting. meta- analysis of observational studies in 
epidemiology (moose) group. JAMA 2000;283:2008–12.
 6 liberati a, altman Dg, Tetzlaff J, et al. The PrisMa statement for reporting systematic 
reviews and meta- analyses of studies that evaluate healthcare interventions: 
explanation and elaboration. BMJ 2009;339:b2700.
 7 singhi aD, ishida h, ali sZ, et al. a histomorphologic comparison of familial and 
sporadic pancreatic cancers. Pancreatology 2015;15:387–91.
 8 hutchings D, Jiang Z, skaro M, et al. histomorphology of pancreatic cancer in 
patients with inherited aTM serine/threonine kinase pathogenic variants. Mod Pathol 
2019;32:1806–13.
 9 gordon- Dseagu Vl, Devesa ss, goggins M, et al. Pancreatic cancer incidence trends: 
evidence from the surveillance, epidemiology and end results (seer) population- based 
data. Int J Epidemiol 2018;47:427–39.
 10 cancer genome atlas research network. electronic address:  andrew_ 
aguirre@ dfci. harvard. edu, cancer genome atlas research network. integrated 
genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 
2017;32:e13:185–203.
 11 han hJ, Yanagisawa a, Kato Y, et al. genetic instability in pancreatic cancer and poorly 
differentiated type of gastric cancer. Cancer Res 1993;53:5087–9.
 12 seymour aB, hruban rh, redston M, et al. allelotype of pancreatic adenocarcinoma. 
Cancer Res 1994;54:2761–4.
 13 Brentnall Ta, chen r, lee Jg, et al. Microsatellite instability and K- ras mutations 
associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 
1995;55:4264–7.
 14 abe T, Ouyang h, Migita T, et al. The somatic mutation frequency of the transforming 
growth factor beta receptor type ii gene varies widely among different cancers with 
microsatellite instability. Eur J Surg Oncol 1996;22:474–7.
 15 Venkatasubbarao K, ahmed MM, swiderski c, et al. novel mutations in the 
polyadenine tract of the transforming growth factor beta type ii receptor gene 
are found in a subpopulation of human pancreatic adenocarcinomas. Genes 
Chromosomes Cancer 1998;22:138–44.
 16 Ouyang h, Furukawa T, abe T, et al. The Bax gene, the promoter of apoptosis, 
is mutated in genetically unstable cancers of the colorectum, stomach, and 
endometrium. Clin Cancer Res 1998;4:1071–4.
 17 goggins M, Offerhaus gJ, hilgers W, et al. Pancreatic adenocarcinomas with Dna 
replication errors (rer+) are associated with wild- type K- ras and characteristic 
histopathology. poor differentiation, a syncytial growth pattern, and pushing borders 
suggest rer+. Am J Pathol 1998;152:1501–7.
 18 ghimenti c, Tannergård P, Wahlberg s, et al. Microsatellite instability and mismatch 
repair gene inactivation in sporadic pancreatic and colon tumours. Br J Cancer 
1999;80:11–16.
 19 caligo Ma, ghimenti c, sensi e, et al. Microsatellite alterations and K- ras, TgFbetarii, 
igFrii and Bax mutations in sporadic cancers of the gastrointestinal tract. Oncol Rep 
2000;7:1371–5.
 20 Wilentz re, goggins M, redston M, et al. genetic, immunohistochemical, and clinical 
features of medullary carcinoma of the pancreas: a newly described and characterized 
entity. Am J Pathol 2000;156:1641–51.
 21 Ueki T, Toyota M, sohn T, et al. hypermethylation of multiple genes in pancreatic 
adenocarcinoma. Cancer Res 2000;60:1835–9.
 22 Yamamoto h, itoh F, nakamura h, et al. genetic and clinical features of human 
pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer 
Res 2001;61:3139–44.
 23 Moriyama h, Matsubara n, Kanbara T, et al. allelic imbalance and microsatellite 
instability in plasma Dna released from polyclonal pancreatic adenocarcinoma. Int J 
Oncol 2002;21:949–56.
 24 nakata B, Wang YQ, Yashiro M, et al. Prognostic value of microsatellite instability in 
resectable pancreatic cancer. Clin Cancer Res 2002;8:2536–40.
 25 Tomaszewska r, Okoń K, stachura J. expression of the Dna mismatch repair proteins 
(hMlh1 and hMsh2) in infiltrating pancreatic cancer and its relation to some 
phenotypic features. Pol J Pathol 2003;54:313–7.
 26 lüttges J, Beyser K, Pust s, et al. Pancreatic mucinous noncystic (colloid) carcinomas 
and intraductal papillary mucinous carcinomas are usually microsatellite stable. Mod 
Pathol 2003;16:537–42.
 27 nakata B, Wang YQ, Yashiro M, et al. negative hMsh2 protein expression in 
pancreatic carcinoma may predict a better prognosis of patients. Oncol Rep 
2003;10:997–1000.
 28 Maple JT, smyrk Tc, Boardman la, et al. Defective Dna mismatch repair in 
long- term (> or =3 years) survivors with pancreatic cancer. Pancreatology 
2005;5:220–8.
 29 Fujii K, Miyashita K, Yamada Y, et al. simulation- Based analyses reveal stable 
microsatellite sequences in human pancreatic cancer. Cancer Genet Cytogenet 
2009;189:5–14.
 30 laghi l, Beghelli s, spinelli a, et al. irrelevance of microsatellite instability in 
the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One 
2012;7:e46002.
 31 Ottenhof na, Morsink FhM, Ten Kate F, et al. Multivariate analysis of 
immunohistochemical evaluation of protein expression in pancreatic ductal 
adenocarcinoma reveals prognostic significance for persistent smad4 expression only. 
Cell Oncol 2012;35:119–26.
 32 Mitsuhashi K, nosho K, sukawa Y, et al. association of Fusobacterium species 
in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 
2015;6:7209–20.
 33 riazy M, Kalloger se, sheffield Bs, et al. Mismatch repair status may predict response 
to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod 
Pathol 2015;28:1383–9.
 34 grant rc, selander i, connor aa, et al. Prevalence of germline mutations in 
cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 
2015;148:556–64.
 35 connor aa, Denroche re, Jang gh, et al. association of distinct mutational signatures 
with correlates of increased immune activity in pancreatic ductal adenocarcinoma. 
JAMA Oncol 2017;3:774–83.
 36 humphris Jl, Patch a- M, nones K, et al. hypermutation in pancreatic cancer. 
Gastroenterology 2017;152:68–74.
 37 salem Me, Puccini a, grothey a, et al. landscape of tumor mutation load, mismatch 
repair deficiency, and PD- l1 expression in a large patient cohort of gastrointestinal 
cancers. Mol Cancer Res 2018;16:805–12.
9luchini c, et al. Gut 2020;0:1–9. doi:10.1136/gutjnl-2020-320726
Pancreas
 38 lupinacci rM, goloudina a, Buhard O, et al. Prevalence of microsatellite instability 
in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 
2018;154:1061–5.
 39 Wartenberg M, cibin s, Zlobec i, et al. integrated genomic and immunophenotypic 
classification of pancreatic cancer reveals three distinct subtypes with Prognostic/
Predictive significance. Clin Cancer Res 2018;24:4444–54.
 40 hu Zi, shia J, stadler ZK, et al. evaluating mismatch repair deficiency in 
pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 
2018;24:1326–36.
 41 Mori T, hamaya Y, Uotani T, et al. Prevalence of elevated microsatellite alterations 
at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma. PLoS One 
2018;13:e0208557.
 42 latham a, srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the 
presence of lynch syndrome pan- cancer. J Clin Oncol 2019;37:286–95.
 43 Kato s, hayashi T, suehara Y, et al. Multicenter experience with large panel next- 
generation sequencing in patients with advanced solid cancers in Japan. Jpn J Clin 
Oncol 2019;49:174–82.
 44 singhi aD, george B, greenbowe Jr, et al. real- Time targeted genome profile 
analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that 
might be targeted with existing drugs or used as biomarkers. Gastroenterology 
2019;156:2242–53.
 45 albacker la, Wu J, smith P, et al. loss of function JaK1 mutations occur at high 
frequency in cancers with microsatellite instability and are suggestive of immune 
evasion. PLoS One 2017;12:e0176181.
 46 garcía- sanz P, Triviño Jc, Mota a, et al. chromatin remodelling and Dna repair 
genes are frequently mutated in endometrioid endometrial carcinoma. Int J Cancer 
2017;140:1551–63.
 47 Boland cr, Thibodeau sn, hamilton sr, et al. a national cancer institute workshop on 
microsatellite instability for cancer detection and familial predisposition: development 
of international criteria for the determination of microsatellite instability in colorectal 
cancer. Cancer Res 1998;58:5248–57.
 48 lupinacci rM, Bachet J- B, andré T, et al. Pancreatic ductal adenocarcinoma harboring 
microsatellite instability / Dna mismatch repair deficiency. towards personalized 
medicine. Surg Oncol 2019;28:121–7.
 49 scarpa a, Di Pace c, Talamini g, et al. cancer of the ampulla of Vater: chromosome 
17p allelic loss is associated with poor prognosis. Gut 2000;46:842–8.
 50 amato e, Molin MD, Mafficini a, et al. Targeted next- generation sequencing of 
cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the 
pancreas. J Pathol 2014;233:217–27.
 51 adsay V, Ohike n, Tajiri T, et al. ampullary region carcinomas: definition and site 
specific classification with delineation of four clinicopathologically and prognostically 
distinct subsets in an analysis of 249 cases. Am J Surg Pathol 2012;36:1592–608.
 52 adsay nV, andea a, Basturk O, et al. secondary tumors of the pancreas: an analysis 
of a surgical and autopsy database and review of the literature. Virchows Arch 
2004;444:527–35.
 53 O’reilly eM, hechtman JF. Tumour response to Trk inhibition in a patient with 
pancreatic adenocarcinoma harbouring an nTrK gene fusion. Ann Oncol 
2019;30:viii36–40.
 54 schrock aB, Ouyang c, sandhu J, et al. Tumor mutational burden is predictive of 
response to immune checkpoint inhibitors in Msi- high metastatic colorectal cancer. 
Ann Oncol 2019;30:1096–103.
 55 lemery s, Keegan P, Pazdur r. First FDa approval agnostic of cancer site - When a 
Biomarker Defines the indication. N Engl J Med 2017;377:1409–12.
 56 le DT, Durham Jn, smith Kn, et al. Mismatch repair deficiency predicts response of 
solid tumors to PD-1 blockade. Science 2017;357:409–13.
 57 Marabelle a, le DT, ascierto Pa, et al. efficacy of pembrolizumab in patients with 
noncolorectal high microsatellite instability/Mismatch repair- deficient cancer: results 
from the phase ii KeYnOTe-158 study. J Clin Oncol 2020;38:1–10.
